JP5763098B2 - 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 - Google Patents

腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 Download PDF

Info

Publication number
JP5763098B2
JP5763098B2 JP2012544950A JP2012544950A JP5763098B2 JP 5763098 B2 JP5763098 B2 JP 5763098B2 JP 2012544950 A JP2012544950 A JP 2012544950A JP 2012544950 A JP2012544950 A JP 2012544950A JP 5763098 B2 JP5763098 B2 JP 5763098B2
Authority
JP
Japan
Prior art keywords
hyaluronic acid
hours
subject
immunoglobulin
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012544950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515243A5 (enExample
JP2013515243A (ja
Inventor
アンダーバーグ，ジョセフ
グレイ，ジェフ
マクファーソン，ポール
ナカムラ，ケビン
カンプ，ジェームス，パトリック
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2013515243A publication Critical patent/JP2013515243A/ja
Publication of JP2013515243A5 publication Critical patent/JP2013515243A5/ja
Application granted granted Critical
Publication of JP5763098B2 publication Critical patent/JP5763098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012544950A 2009-12-20 2010-12-20 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 Active JP5763098B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US28832709P 2009-12-20 2009-12-20
US61/288,327 2009-12-20
US30886110P 2010-02-26 2010-02-26
US61/308,861 2010-02-26
US41087510P 2010-11-06 2010-11-06
US41088010P 2010-11-06 2010-11-06
US41087910P 2010-11-06 2010-11-06
US41087810P 2010-11-06 2010-11-06
US61/410,879 2010-11-06
US61/410,880 2010-11-06
US61/410,875 2010-11-06
US61/410,878 2010-11-06
PCT/US2010/061377 WO2011075744A1 (en) 2009-12-20 2010-12-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237875A Division JP6309434B2 (ja) 2009-12-20 2014-11-25 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Publications (3)

Publication Number Publication Date
JP2013515243A JP2013515243A (ja) 2013-05-02
JP2013515243A5 JP2013515243A5 (enExample) 2014-01-23
JP5763098B2 true JP5763098B2 (ja) 2015-08-12

Family

ID=44167738

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012544950A Active JP5763098B2 (ja) 2009-12-20 2010-12-20 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2014237875A Active JP6309434B2 (ja) 2009-12-20 2014-11-25 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014237875A Active JP6309434B2 (ja) 2009-12-20 2014-11-25 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Country Status (13)

Country Link
US (3) US10830773B2 (enExample)
EP (2) EP3112871B1 (enExample)
JP (2) JP5763098B2 (enExample)
KR (2) KR20120123056A (enExample)
CN (2) CN102725636B (enExample)
AU (2) AU2010330735B2 (enExample)
CA (1) CA2784889C (enExample)
EA (1) EA201290387A1 (enExample)
ES (2) ES2818138T3 (enExample)
HK (1) HK1211082A1 (enExample)
MX (1) MX342967B (enExample)
NZ (3) NZ600828A (enExample)
WO (1) WO2011075744A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ610356A (en) 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9057735B2 (en) 2008-08-29 2015-06-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (ja) 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
NZ599105A (en) * 2009-09-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290192A1 (ru) 2009-11-07 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
DK2666872T3 (en) * 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
US20130203074A1 (en) 2010-06-23 2013-08-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103080743B (zh) * 2010-06-23 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013541005A (ja) * 2010-09-24 2013-11-07 アスチュート メディカル，インコーポレイテッド ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
CA2841880A1 (en) * 2011-07-09 2013-01-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2721907T3 (es) * 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US20140315752A1 (en) * 2011-11-22 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20150293131A1 (en) * 2012-04-02 2015-10-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
WO2013163345A1 (en) * 2012-04-24 2013-10-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
HK1207155A1 (en) * 2012-08-03 2016-01-22 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2882767B1 (en) * 2012-08-11 2023-07-12 Astute Medical, Inc. Evaluating renal injury using hyaluronic acid
EP4075143A1 (en) 2012-09-12 2022-10-19 Roche Diagnostics GmbH Identification of patients with abnormal fractional shortening
US20150293085A1 (en) * 2012-10-31 2015-10-15 Astute Medical, Inc. Quantitative lateral flow assay
CA3158996C (en) * 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20160003850A1 (en) * 2013-02-26 2016-01-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10408828B2 (en) 2013-02-26 2019-09-10 Astute Medical, Inc. Lateral flow assay with test strip retainer
MX391220B (es) 2013-05-14 2025-03-21 Metabolon Inc Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
US20160146832A1 (en) * 2013-06-05 2016-05-26 Lakhmir S. Chawla Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2015021308A1 (en) 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
MX375701B (es) 2013-11-06 2025-03-06 Astute Medical Inc Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
CN105917229B (zh) * 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
MX388231B (es) 2014-10-20 2025-03-19 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.
WO2016083374A1 (en) 2014-11-25 2016-06-02 F. Hoffmann-La Roche Ag Biomarkers of fast progression of chronic kidney disease
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017246588A1 (en) * 2016-04-08 2018-09-27 Centre National De La Recherche Scientifique - Cnrs - Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
AU2017277305A1 (en) * 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
JP7109424B2 (ja) 2016-08-17 2022-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体液に基づくセルフリーＤＮＡ（ｃｆＤＮＡ）アッセイを通して臓器損傷状態を査定するための新規のイムノプローブに基づく方法
US20190263926A1 (en) 2016-10-28 2019-08-29 Astute Medical, Inc. Use of Antibodies to TIMP-2 for the Improvement of Renal Function
EP4063853A1 (en) * 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
US11346846B2 (en) * 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法
CN110753700A (zh) * 2017-05-07 2020-02-04 机敏医药股份有限公司 胰岛素样生长因子结合蛋白7和金属蛋白酶2组织抑制物在肾脏替代疗法的管理中的用途
US11771113B2 (en) 2017-05-31 2023-10-03 Mars, Incorporated Methods of diagnosing and treating chronic kidney disease
WO2019138430A1 (en) * 2018-01-15 2019-07-18 Shukla Rashmi A time-based semi-quantitative and quantitative lateral flow assay (lfa) for early detection of renal injury
WO2019144081A1 (en) 2018-01-19 2019-07-25 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits
US20210327589A1 (en) 2018-07-14 2021-10-21 Mars, Incorporated Biomarkers and test models for chronic kidney disease
CN111289756A (zh) * 2018-12-10 2020-06-16 北京师范大学 卵巢癌肺转移成瘤相关的尿液标志物
RU2726314C1 (ru) * 2019-11-15 2020-07-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования
CN113252895A (zh) * 2020-02-10 2021-08-13 首都医科大学附属北京世纪坛医院 血清组织蛋白酶d在淋巴水肿疾病中的应用
CA3178400A1 (en) 2020-06-01 2021-12-09 Ilias TAGKOPOULOS System and method for chronic kidney disease of a dog
CN111999363B (zh) * 2020-08-17 2022-09-02 遵义医科大学附属医院 一种用于kim-1蛋白的无酶电化学免疫检测系统及其制备和使用方法
EP4263383A4 (en) 2020-12-17 2024-10-23 Nephrosant, Inc. KITS FOR STABILIZATION OF URINE SAMPLES
CN113552369B (zh) * 2021-07-23 2023-10-20 江苏省中医院 蛋白标志物联合用于2型糖尿病、2型糖尿病肾病的诊断的用途

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998057U (ja) 1982-12-23 1984-07-03 東陶機器株式会社 ユニツトバスル−ム
SU1429031A1 (ru) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
US5118614A (en) 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1997044460A1 (en) 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0984984A2 (en) 1997-06-03 2000-03-15 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000036105A1 (en) * 1998-12-18 2000-06-22 Human Genome Sciences, Inc. Prostacyclin-stimulating factor-2
AU1674400A (en) 1998-12-21 2000-07-12 Monash University Kidney disease detection and treatment
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1261875B1 (en) 2000-03-10 2007-08-01 Universite de Geneve Diagnostic assay for transmissible spongiform encephalopathies
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
EP1405072A2 (en) 2000-12-29 2004-04-07 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
BR0211468A (pt) 2001-07-24 2004-11-23 Univ Yale Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero
JP2003081838A (ja) 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) * 2001-12-20 2002-02-06 Serono Internat S A Proteins
US20070233391A1 (en) 2002-03-07 2007-10-04 Cambridge University Technical Service Limited (CUTS) Scd fingerprints
AU2003214604A1 (en) 2002-03-21 2003-10-08 Hadasit Medical Research Services And Development Ltd. Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
AU2003300823A1 (en) 2002-12-06 2004-06-30 Sandia Corporation Outcome prediction and risk classification in childhood leukemia
WO2004059293A2 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1791797A (zh) 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
WO2005017203A2 (en) 2003-07-11 2005-02-24 Yale University Systems and methods for diagnosing and treating psychological and behavioral conditions
WO2005010213A2 (en) 2003-07-17 2005-02-03 Pacific Edge Biotechnology, Ltd. Markers for detection of gastric cancer
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
EP1727564A1 (en) 2004-03-17 2006-12-06 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
WO2005103281A2 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (fr) 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
WO2006008661A2 (en) * 2004-07-19 2006-01-26 Neurochem (International) Limited Diagnostic methods of multiple organ amyloidosis
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US20100009462A1 (en) 2004-07-28 2010-01-14 Andreas Christ Timp-2 as target/marker of beta cell failure
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
FI20050011L (fi) 2005-01-05 2006-07-06 Jurilab Ltd Oy Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
CA2596469A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
ITVI20050059A1 (it) 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
JP2008537875A (ja) 2005-03-14 2008-10-02 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 固形臓器移植レシピエントにおいて移植片生着を評価するための方法および組成物
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
EP1871909A4 (en) 2005-03-31 2010-05-19 Univ Leland Stanford Junior COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDER
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2006111029A1 (en) 2005-04-18 2006-10-26 Genesis Genomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
CA2624569A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
CN101361001A (zh) 2006-01-20 2009-02-04 马赛奎斯诊断和治疗有限公司 诊断肾病的方法和标志物
US7623910B2 (en) 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
WO2007124331A2 (en) 2006-04-19 2007-11-01 Virginia Commonwealth University Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
CA2592372A1 (en) 2006-06-20 2007-12-20 Institut De Cardiologie De Montreal Angiopoietin-like 2 as a biomarker of vascular endothelial cell abnormal function and senescence
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090298073A1 (en) 2006-06-30 2009-12-03 Gerhold David L Kidney Toxicity Biomarkers
WO2008009132A1 (en) 2006-07-21 2008-01-24 The Governors Of The University Of Alberta Tissue rejection
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
WO2008073899A2 (en) 2006-12-08 2008-06-19 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
PL2115477T3 (pl) 2007-01-25 2015-12-31 Hoffmann La Roche Zastosowanie IGFBP-7 do oceny niewydolności serca
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2479568B1 (en) 2007-03-26 2015-01-07 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
EP2134866A2 (en) 2007-04-10 2009-12-23 Integragen Human diabetes susceptibility tnfrsf10b gene
EP2134874A4 (en) * 2007-04-10 2010-12-22 Univ Nat Taiwan PROGNOSIS OF SURVIVAL RATE OF PATIENTS AFTER TREATMENT WITH miRNA
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
WO2008150488A1 (en) 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
JP5661457B2 (ja) 2007-06-06 2015-01-28 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 腎疾患の予測診断
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
EP2637020A3 (en) 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US8039227B2 (en) 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
US20100304413A1 (en) 2007-11-15 2010-12-02 Lars Otto Uttenthal Diagnostic use of individual molecular forms of a biomarker
BRPI0820793A2 (pt) 2007-12-10 2015-06-16 Hoffmann La Roche Seprase como marcador de câncer
US8592925B2 (en) 2008-01-11 2013-11-26 Seiko Epson Corporation Functional device with functional structure of a microelectromechanical system disposed in a cavity of a substrate, and manufacturing method thereof
KR20100122495A (ko) 2008-02-29 2010-11-22 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 급성 신장 장해 및 예후 추정용 바이오마커 및 그 용도
WO2009146450A2 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for monitoring immunosuppressant drug levels, renal function, and hepatic function using small volume samples
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US7998744B2 (en) 2008-07-28 2011-08-16 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
US8673574B2 (en) 2008-08-21 2014-03-18 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
NZ610356A (en) 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9057735B2 (en) 2008-08-29 2015-06-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104020284B (zh) 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2751435A1 (en) 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010230855A1 (en) 2009-04-03 2012-01-12 Vegenics Limited Anti-VEGF-D antibodies
US8313949B2 (en) 2009-04-16 2012-11-20 Nextcea Inc. Detecting phospholipidosis and diagnosing lysosomal storage disorders
CN102414566B (zh) 2009-04-23 2015-04-01 沃莱克公司 确定母体健康风险的方法
EP2427494B1 (en) 2009-05-08 2017-10-18 Novartis AG Methods of modulating fibrosis using bone morphogenetic protein-9 (bmp-9) modulators
US8974491B2 (en) 2009-06-23 2015-03-10 Infarct Reduction Technologies Inc. Methods for adaptive limb occlusion
NZ598035A (en) 2009-08-07 2014-06-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462443A4 (en) 2009-08-07 2013-01-30 Rules Based Medicine Inc METHODS AND DEVICES FOR DETECTING GLOMERULONEPHRITH AND ASSOCIATED DISORDERS
CN102792161B (zh) 2009-08-28 2014-11-12 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后的方法及组合物
NZ599105A (en) 2009-09-21 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DK2666872T3 (en) 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
US20120329071A1 (en) 2010-03-05 2012-12-27 Mark Chance Protein biomarkers and therapeutic targets for renal disorders
US20130210043A1 (en) 2010-06-23 2013-08-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
WO2013006629A1 (en) 2011-07-06 2013-01-10 Alere San Diego Inc. Methods and compositions for assigning likelihood of acute kidney injury progression
ES2721907T3 (es) 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20150293085A1 (en) 2012-10-31 2015-10-15 Astute Medical, Inc. Quantitative lateral flow assay
CA2886698C (en) 2012-11-09 2019-02-19 Dirk Block Tnt based diagnosis of paroxysmal atrial fibrillation
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
TWI558403B (zh) 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
US20160146832A1 (en) 2013-06-05 2016-05-26 Lakhmir S. Chawla Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2015021308A1 (en) 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
MX375701B (es) 2013-11-06 2025-03-06 Astute Medical Inc Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN108139409B (zh) 2015-10-08 2020-07-24 豪夫迈·罗氏有限公司 当在外科手术之前测量时用于预测aki的风险的igfbp7
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US20190263926A1 (en) 2016-10-28 2019-08-29 Astute Medical, Inc. Use of Antibodies to TIMP-2 for the Improvement of Renal Function
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法
CN110753700A (zh) 2017-05-07 2020-02-04 机敏医药股份有限公司 胰岛素样生长因子结合蛋白7和金属蛋白酶2组织抑制物在肾脏替代疗法的管理中的用途

Also Published As

Publication number Publication date
CN104698161A (zh) 2015-06-10
US20170343562A1 (en) 2017-11-30
NZ600828A (en) 2014-09-26
HK1171260A1 (en) 2013-03-22
EP2513649A4 (en) 2013-07-03
CN102725636B (zh) 2015-04-01
US20220187319A1 (en) 2022-06-16
WO2011075744A1 (en) 2011-06-23
CN102725636A (zh) 2012-10-10
EP2513649A1 (en) 2012-10-24
ES2818138T3 (es) 2021-04-09
JP6309434B2 (ja) 2018-04-11
US12123882B2 (en) 2024-10-22
AU2014227447A1 (en) 2014-10-02
AU2010330735B2 (en) 2014-11-27
KR20180063352A (ko) 2018-06-11
JP2015064371A (ja) 2015-04-09
US10830773B2 (en) 2020-11-10
US20120283128A1 (en) 2012-11-08
EA201290387A1 (ru) 2013-02-28
CA2784889C (en) 2018-06-19
EP3112871A1 (en) 2017-01-04
CA2784889A1 (en) 2011-06-23
AU2010330735A1 (en) 2012-07-19
KR102003258B1 (ko) 2019-07-24
ES2592386T3 (es) 2016-11-29
MX2012007082A (es) 2012-11-06
EP2513649B1 (en) 2016-04-20
NZ625423A (en) 2015-02-27
US11262363B2 (en) 2022-03-01
KR20120123056A (ko) 2012-11-07
JP2013515243A (ja) 2013-05-02
NZ702527A (en) 2016-07-29
MX342967B (es) 2016-10-19
EP3112871B1 (en) 2020-07-29
HK1211082A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
JP5763098B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6363154B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6054481B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2020112568A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2017032586A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP5981144B2 (ja) 腎損傷および腎不全の診断および予後診断
JP6321080B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP5827226B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2012517594A (ja) 腎損傷および腎不全の診断および予後診断のための方法および組成物
JP6185035B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016194526A (ja) 腎損傷および腎不全の診断および予後診断のための方法および組成物
JP2017026627A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6403712B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016136154A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6186400B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2014521088A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015508181A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015524926A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015513673A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016505860A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150610

R150 Certificate of patent or registration of utility model

Ref document number: 5763098

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250